Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11338011 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11141457 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(14 years from now) | |
| US10695397 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US12251418 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US12246054 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US8535695 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US10238709 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11510963 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11857595 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11052126 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11890316 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(14 years from now) | |
| US11986529 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US11969471 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US8329198 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US9265812 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US9566246 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
| Orphan Drug Exclusivity(ODE-474) | Jun 26, 2027 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Dosage: CAPSULE, DELAYED RELEASE